EUCTR2008-004753-14-DEActive, not recruitingPhase 1
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis - ENDORSE
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Biogen Idec Ltd.
- Enrollment
- 1,738
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. Ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorisation to use protected health information (PHI) in accordance with national and local subject privacy regulations.
- •2. Subjects who participated in and completed as per protocol previous BG00012 clinical studies 109MS301 and 109MS302, including those subjects who received an open-label, approved MS therapy and completed the modified visit schedule.
- •3. All male and female subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for 30 days after their last dose of BG00012.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 1738
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Reasons for study exclusion include:
- •1. Any significant change in medical history in subjects from 109MS301 or 109MS302, including laboratory tests, or current clinically significant condition that in the opinion of the Investigator would have excluded the subjects' participation from their previous study. The Investigator must re-review the subject's medical fitness for participation and consider any diseases that would preclude treatment.
- •2. Subjects from 109MS301 or 109MS302 who discontinued BG00012 due to an AE or due to reasons other than protocol-defined relapse/disability progression.
- •3. Subjects from 109MS301 or 109MS302 who discontinued BG00012 due to disability progression or relapses and did not follow the modified weekly schedule up to Week 96.
- •4. History of malignancy.
- •5. History of severe allergic or anaphylactic reactions.
- •6. Alanine transaminase (ALT), aspartate transaminase (AST), or gamma-glutamyltransferase >3 times the upper limit of normal (ULN)
- •7. Female subjects considering becoming pregnant while in the study, currently pregnant, or breast feeding.
- •8. Previous participation in this study (109MS303).
- •9. Unwillingness or inability to comply with the requirements of the protocol including the presence of any condition (physical, mental, or social) that is likely to affect the subject’s ability to comply with the protocol.
- •10. Other unspecified reasons that, in the opinion of the Investigator or Biogen, make the subject unsuitable for enrollment.
Investigators
Similar Trials
Completed
Phase 3
A Dose-Blind, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in Subjects with Relapsing-Remitting Multiple Sclerosis10012303MSmultiple sclerosisNL-OMON47336Biogen4
Active, not recruiting
Phase 1
ong-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2008-004753-14-CZBiogen Idec Limited1,738
Active, not recruiting
Phase 1
ong-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 20.0 Level: PT Classification code 10063399 Term: Relapsing-remitting multiple sclerosis System Organ Class: 10029205 - Nervous system disordersEUCTR2008-004753-14-ATBiogen Idec Limited1,738
Completed
Phase 3
A dose blind extension clinical trial to determine the Long-Term Safety and Efficacy of Two Doses of BG00012 Monotherapy in patients with relapsing remitting multiple sclerosis.CTRI/2010/091/000288Biogen Idec1,700
Active, not recruiting
Phase 1
ong-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple SclerosisRelapsing-Remitting Multiple SclerosisMedDRA version: 20.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2008-004753-14-SKBiogen Idec Limited1,738